145 related articles for article (PubMed ID: 36962423)
41. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves.
Kim SY; Salomon JA; Goldie SJ
Bull World Health Organ; 2007 Nov; 85(11):833-42. PubMed ID: 18038073
[TBL] [Abstract][Full Text] [Related]
42. The cost-effectiveness of alternative polio immunization policies in South Africa.
Griffiths UK; Botham L; Schoub BD
Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
[TBL] [Abstract][Full Text] [Related]
43. Net benefit and cost-effectiveness of universal iron-containing multiple micronutrient powders for young children in 78 countries: a microsimulation study.
Pasricha SR; Gheorghe A; Sakr-Ashour F; Arcot A; Neufeld L; Murray-Kolb LE; Suchdev PS; Bode M
Lancet Glob Health; 2020 Aug; 8(8):e1071-e1080. PubMed ID: 32710863
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of maternal pertussis immunization: Implications of a dynamic transmission model for low- and middle-income countries.
Kim SY; Min KD; Jung SM; Russell LB; Toscano C; Minamisava R; Andrade ALS; Sanderson C; Sinha A
Vaccine; 2021 Jan; 39(1):147-157. PubMed ID: 33303182
[TBL] [Abstract][Full Text] [Related]
45. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
46. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique.
Alonso S; Cambaco O; Maússe Y; Matsinhe G; Macete E; Menéndez C; Sicuri E; Sevene E; Munguambe K
BMC Public Health; 2019 Aug; 19(1):1031. PubMed ID: 31370810
[TBL] [Abstract][Full Text] [Related]
47. Estimating the future global dose demand for measles-rubella microarray patches.
Ko M; Malvolti S; Cherian T; Mantel C; Biellik R; Jarrahian C; Menozzi-Arnaud M; Amorij JP; Christiansen H; Papania MJ; Meltzer MI; Masresha BG; Pastor D; Durrheim DN; Giersing B; Hasso-Agopsowicz M
Front Public Health; 2022; 10():1037157. PubMed ID: 36726626
[TBL] [Abstract][Full Text] [Related]
48. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.
Loganathan T; Ng CW; Lee WS; Hutubessy RCW; Verguet S; Jit M
Health Policy Plan; 2018 Mar; 33(2):204-214. PubMed ID: 29228339
[TBL] [Abstract][Full Text] [Related]
49. Male circumcision at different ages in Rwanda: a cost-effectiveness study.
Binagwaho A; Pegurri E; Muita J; Bertozzi S
PLoS Med; 2010 Jan; 7(1):e1000211. PubMed ID: 20098721
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
[TBL] [Abstract][Full Text] [Related]
51. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
Kim SY; Lee G; Goldie SJ
BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of revised WHO guidelines for management of childhood pneumonia in 74 Countdown countries.
Zhang S; Incardona B; Qazi SA; Stenberg K; Campbell H; Nair H;
J Glob Health; 2017 Jun; 7(1):010409. PubMed ID: 28400955
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS
Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544
[TBL] [Abstract][Full Text] [Related]
54. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
Whittles LK; Didelot X; White PJ
Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
[TBL] [Abstract][Full Text] [Related]
55. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
[TBL] [Abstract][Full Text] [Related]
57. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of norovirus vaccination in children in Peru.
Mirelman AJ; Ballard SB; Saito M; Kosek MN; Gilman RH
Vaccine; 2015 Jun; 33(27):3084-91. PubMed ID: 25980428
[TBL] [Abstract][Full Text] [Related]
59. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of hepatitis A vaccination in Indonesia.
Suwantika AA; Beutels P; Postma MJ
Hum Vaccin Immunother; 2014; 10(8):2342-9. PubMed ID: 25424941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
